132 related articles for article (PubMed ID: 23085464)
21. Silencing HO-1 sensitizes SKM-1 cells to apoptosis induced by low concentration 5-azacytidine through enhancing p16 demethylation.
Wang P; Ma D; Wang J; Fang Q; Gao R; Wu W; Lu T; Cao L
Int J Oncol; 2015 Mar; 46(3):1317-27. PubMed ID: 25585641
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.
Gao XN; Lin J; Li YH; Gao L; Wang XR; Wang W; Kang HY; Yan GT; Wang LL; Yu L
Oncogene; 2011 Aug; 30(31):3416-28. PubMed ID: 21399664
[TBL] [Abstract][Full Text] [Related]
23. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
24. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
Sekeres MA; O'Keefe C; List AF; Paulic K; Afable M; Englehaupt R; Maciejewski JP
Am J Hematol; 2011 Jan; 86(1):102-3. PubMed ID: 21080340
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
[TBL] [Abstract][Full Text] [Related]
26. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
[TBL] [Abstract][Full Text] [Related]
27. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
28. Hsp27: a novel therapeutic target for pediatric M4/M5 acute myeloid leukemia.
Yang L; Cao L; Yang M; Tang D; Kang R; Min X; Zhu S; Yu Y
Oncol Rep; 2013 Apr; 29(4):1459-66. PubMed ID: 23404246
[TBL] [Abstract][Full Text] [Related]
29. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
Ozbalak M; Cetiner M; Bekoz H; Atesoglu EB; Ar C; Salihoglu A; Tuzuner N; Ferhanoglu B
Hematol Oncol; 2012 Jun; 30(2):76-81. PubMed ID: 21387357
[TBL] [Abstract][Full Text] [Related]
30. Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2.
Xu Z; Shier L; Sabloff M; McCurdy A; Sheppard D; Bredeson C
Br J Haematol; 2014 Oct; 167(2):147. PubMed ID: 25040664
[No Abstract] [Full Text] [Related]
31. Gene Expression and DNA Methylation Profiling Suggest Potential Biomarkers for Azacitidine Resistance in Myelodysplastic Syndrome.
Kim DY; Shin DY; Oh S; Kim I; Kim EJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731939
[TBL] [Abstract][Full Text] [Related]
32. Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Cluzeau T; Furstoss N; Savy C; El Manaa W; Zerhouni M; Blot L; Calleja A; Dufies M; Dubois A; Ginet C; Mounier N; Garnier G; Raynaud S; Rohrlich PS; Peterlin P; Stamatoullas A; Chermat F; Fenaux P; Jacquel A; Robert G; Auberger P
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881723
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of resistance to azacitidine in human leukemia cell lines.
Sripayap P; Nagai T; Uesawa M; Kobayashi H; Tsukahara T; Ohmine K; Muroi K; Ozawa K
Exp Hematol; 2014 Apr; 42(4):294-306.e2. PubMed ID: 24368162
[TBL] [Abstract][Full Text] [Related]
34. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
Meldi K; Qin T; Buchi F; Droin N; Sotzen J; Micol JB; Selimoglu-Buet D; Masala E; Allione B; Gioia D; Poloni A; Lunghi M; Solary E; Abdel-Wahab O; Santini V; Figueroa ME
J Clin Invest; 2015 May; 125(5):1857-72. PubMed ID: 25822018
[TBL] [Abstract][Full Text] [Related]
35. A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.
Asano M; Ohyashiki JH; Kobayashi-Kawana C; Umezu T; Imanishi S; Azuma K; Akahane D; Fujimoto H; Ito Y; Ohyashiki K
Drug Des Devel Ther; 2019; 13():1821-1833. PubMed ID: 31239639
[No Abstract] [Full Text] [Related]
36. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT; Kontandreopoulou CN; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Vassilakopoulos T; Dimou M; Solomou E; Kyrtsonis MC; Siakantaris M; Angelopoulou M; Kourakli A; Papageorgiou S; Christopoulou G; Roumelioti M; Panayiotidis P; Viniou NA;
Ann Hematol; 2019 Jun; 98(6):1383-1392. PubMed ID: 30877373
[TBL] [Abstract][Full Text] [Related]
37. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM
Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654
[No Abstract] [Full Text] [Related]
38. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
[TBL] [Abstract][Full Text] [Related]
39. A Comparative Study on the In Vitro Effects of the DNA Methyltransferase Inhibitor 5-Azacytidine (5-AzaC) in Breast/Mammary Cancer of Different Mammalian Species.
Harman RM; Curtis TM; Argyle DJ; Coonrod SA; Van de Walle GR
J Mammary Gland Biol Neoplasia; 2016 Jun; 21(1-2):51-66. PubMed ID: 27002722
[TBL] [Abstract][Full Text] [Related]
40. The different faces of myelodysplasia in peripheral blood granulocytes.
Preis M; Ornstein DL
Am J Hematol; 2014 Mar; 89(3):342. PubMed ID: 23828753
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
